CPHI & P-MEC China opens its online international partnering platform as pharmaceutical and biopharmaceutical industries in the country report strong underlying conditions and see increases in all categories of the most recent CPHI Pharma Index  – an annual score of each country’s pharma industry strength – with its overall score rising by 7.2%, the largest increase of any nation.

The two-month digital partnering platform takes on increased importance with the postponement of the in-person exhibition until December (20^th-22^nd) 2022. CPHI & P-MEC China’s online event opened on April 21^st and will continue until June 30^th 2022 and is designed to empower international companies by helping them pre-select new partners and begin discussions earlier.

China recorded the largest year-on-year gains in the CPHI Pharma Index for ‘solid dose manufacturing innovation’, ‘quality of bioprocessing’ and ‘API manufacturing’ – with rises of 9.5%, 11% and 7.4% respectively – and international companies should anticipate the need to source partners much earlier as demand rises. Further fuelling competition for the best manufacturing partners is the increasing numbers of biotechs in the country and the MAH (Marketing Authorization Holder) programme.

The Virtual Expo Connect has been designed to help companies from around the globe meet with over 2500 suppliers and prospective partners. The platform is flexible and allows registered users to either research suppliers themselves or to apply for the Hosted Buyer Programme.  

Additionally, international audiences will be able to gain the latest insights and trends from across China via the Online Content Program with on-demand webinars, including sessions on ‘China-EU Biotech/Medtech Market access’ and ‘Generic Drug Applications’. A weekly pharma news podcast, in association with PharmaVibe, will also be available for the attendees throughout the online event.